Amerise Biosciences Ltd disclosed that Snehjeev Ventures Pvt Ltd, along with its persons acting in concert (PACs), crossed the 9% shareholding threshold in the company on July 20, 2026. This development triggers a mandatory disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The crossing of this regulatory threshold is significant as it marks a substantial increase in outside investor concentration in the Ahmedabad-based biosciences firm.

The acquirer, Snehjeev Ventures Pvt Ltd, acquired 28,000 equity shares through open market transactions. This purchase pushed the group’s aggregate holding from 8.98% to 9.02% of the total voting capital. Prior to this specific acquisition, the group held 5,934,355 shares. Following the addition of the new shares, the total holding stands at 5,962,355 shares. There were no encumbrances, pledges, or liens associated with these acquired securities, nor were there any warrants or convertible instruments involved in the transaction.

The persons acting in concert with Snehjeev Ventures include Rushank SS Lunkad, Sneha Lunkad, Riddhi Lunkad, and Sanjeev Lunkad. Rushank SS Lunkad, a director at Snehjeev Ventures, signed the disclosure document dated July 21, 2026. The disclosure confirms that the acquirer does not belong to the promoter or promoter group of Amerise Biosciences Ltd. The entire holding consists of ordinary equity shares carrying voting rights.

Amerise Biosciences Ltd has an authorized equity share capital structure consisting of 66,06,900 equity shares with a face value of ₹10 each, totaling ₹6,60,69,000. The total diluted share/voting capital remains unaffected by this transaction as no convertible securities were exercised. The company submitted these disclosures to the BSE Limited listing department on July 29, 2026, as required by regulatory norms for substantial acquisitions.

Acquisition Details

What the Numbers Show

The precise nature of the acquisition highlights a strategic accumulation of stake just above the 9% regulatory reporting line. The group moved from 8.98% to 9.02%, indicating that the 28,000-share purchase was likely calculated to trigger or slightly exceed this specific disclosure mandate rather than a bulk block deal. With no encumbrances on the shares, the holding represents clean equity exposure. The fact that the acquirer is not part of the promoter group suggests this is an independent investment move, potentially signaling confidence in the company’s operational trajectory or valuation levels at the time of purchase.

Amerise Biosciences Limited convened a Board of Directors meeting on Tuesday, May 5, 2026, to approve the audited standalone financial results for the year ended March 31, 2026. The meeting, held at Ahmedabad, commenced at 04:45 PM and concluded at 05:15 PM. The statutory auditor, Bipin & Co., Chartered Accountants, issued an audit report with an unmodified opinion on the financial results for the financial year ended March 31, 2026. The results were submitted to BSE Limited pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The company's revenue from operations for FY26 stood at Rs. 25.52 lacs, entirely comprising other operating revenue, compared to Rs. 18.80 lacs in FY25. Total income for FY26 was Rs. 25.52 lacs versus Rs. 18.80 lacs in the prior year. Total expenses for FY26 were Rs. 23.46 lacs against Rs. 18.04 lacs in FY25, driven primarily by other expenses of Rs. 16.09 lacs and employee benefit expenses of Rs. 7.37 lacs. The company recorded a profit before tax of Rs. 2.06 lacs for FY26, compared to Rs. 0.76 lacs in FY25. After accounting for tax expense of Rs. 0.45 lacs (FY25: Rs. 0.19 lacs), net profit after tax for FY26 stood at Rs. 1.61 lacs, up from Rs. 0.57 lacs in FY25.

The following table summarises the key income statement metrics:

Quarterly Performance

For the quarter ended March 31, 2026, the company reported revenue from operations of Rs. 7.92 lacs and total expenses of Rs. 1.79 lacs, resulting in a net profit of Rs. 6.13 lacs. This compares to revenue from operations of Rs. 18.80 lacs and net profit of Rs. 10.59 lacs in the corresponding quarter ended March 31, 2025. For the quarter ended December 31, 2025, revenue from operations was Rs. 4.49 lacs and net profit was Rs. 0.97 lacs.

Balance Sheet Highlights

The company's total assets as at March 31, 2026 stood at Rs. 742.19 lacs, compared to Rs. 846.33 lacs as at March 31, 2025. Non-current assets declined to Rs. 681.00 lacs from Rs. 843.64 lacs, primarily reflecting a decrease in non-current loans from Rs. 605.54 lacs to Rs. 304.03 lacs, partially offset by an increase in investments from Rs. 238.10 lacs to Rs. 376.97 lacs. Current assets increased significantly to Rs. 61.19 lacs from Rs. 2.69 lacs, driven by a rise in bank balances to Rs. 57.42 lacs from Rs. 1.08 lacs.

Cash Flow Summary

The standalone statement of cash flows, prepared under the indirect method as per Ind AS-7, reflects a net decrease in cash from operating activities of Rs. 105.67 lacs for FY26 (FY25: net inflow of Rs. 307.08 lacs), primarily due to a decrease in current liabilities of Rs. 105.75 lacs. Net cash inflow from investing activities was Rs. 162.64 lacs (FY25: outflow of Rs. 306.97 lacs), driven by proceeds from long-term loans and advances of Rs. 301.51 lacs, partially offset by investments in shares of Rs. 138.87 lacs. There were no cash flows from financing activities in either period. The net increase in cash and cash equivalents for FY26 was Rs. 56.97 lacs, resulting in a closing balance of Rs. 59.19 lacs compared to Rs. 2.22 lacs at the start of the year.

Earnings Per Share and Other Details

The paid-up equity share capital of the company remained unchanged at Rs. 660.69 lacs (face value of Rs. 1/- each) as at March 31, 2026. Basic and diluted earnings per share (not annualised) for the full year FY26 were Rs. 0.00 each. The company operates in a single business segment, and accordingly no separate segment results have been disclosed. The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 5, 2026, at Ahmedabad.